NasdaqCM:TGTXBiotechs
TG Therapeutics (TGTX) Q1 2026 Results Put 66% Net Margin Narrative To The Test
TG Therapeutics (TGTX) has just posted Q1 2026 results with revenue of US$204.9 million, basic EPS of US$0.14 and net income of US$19.8 million, putting fresh numbers behind a stock that last closed at US$41.97. The company has seen total revenue move from US$108.2 million in Q4 2024 to US$120.9 million in Q1 2025 and then to US$204.9 million in Q1 2026, while trailing twelve month basic EPS is reported at US$3.21 alongside trailing net profit margin of 66%. Taken together, these figures...